🔖
Cite This Article
DURAN, A., DURAN, A., ÇİLOĞLU, S., PEKCAN, Ş. Y. (2022). Multiple Squamous Cell Carcinoma after Vemurafenib Therapy. Turkish Journal of Plastic Surgery, Cilt: 24 - Sayı: 4, 216–217. https://ajindex.com/articles/614147
Journals / Turkish Journal of Plastic Surgery / 2016 / Cilt: 24 - Sayı: 4
Multiple Squamous Cell Carcinoma after Vemurafenib Therapy
- Pages
- 216–217
- Publication Date
- 2022-11-05
- DOI
- —
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗References (1)
- Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467(7315): 596-9. [CrossRef] 2. Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 2012; 67(6): 1265-72. [CrossRef] 3. Sharma A, Shah RS, Illum H, Dowel J. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. Drugs 2012; 72(17): 2207-22. [CrossRef] 4. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9): 809-19. [CrossRef] 5. Sullivan RJ, Flaherty KT. BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. J Skin Cancer 2011; 2011: 423239.